# Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma

> **NCT03966118** · PHASE2 · UNKNOWN · sponsor: **P. C. Thuss-Patience** · enrollment: 59 (estimated)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma
- Adenocarcinoma of the Stomach

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Ramucirumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03966118
- **Lead sponsor:** P. C. Thuss-Patience
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-01
- **Primary completion:** 2022-09
- **Final completion:** 2023-09
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2019-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03966118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03966118, "Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03966118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*